Last reviewed · How we verify
continuous intra-femoral thrombolysis group — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
continuous intra-femoral thrombolysis group (continuous intra-femoral thrombolysis group) — Xiang Guang-da.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| continuous intra-femoral thrombolysis group TARGET | continuous intra-femoral thrombolysis group | Xiang Guang-da | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- continuous intra-femoral thrombolysis group CI watch — RSS
- continuous intra-femoral thrombolysis group CI watch — Atom
- continuous intra-femoral thrombolysis group CI watch — JSON
- continuous intra-femoral thrombolysis group alone — RSS
Cite this brief
Drug Landscape (2026). continuous intra-femoral thrombolysis group — Competitive Intelligence Brief. https://druglandscape.com/ci/continuous-intra-femoral-thrombolysis-group. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab